An arranged marriage for precision medicine: Hypoxia and genomic assays in localized prostate cancer radiotherapy

British Journal of Radiology

Volumn 87, Issue 1035, 2014, Pages

  Bristow, R G ^a,b   Berlin, A ^a,b   Dal Pra, A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GENOMIC RNA; PROSTATE SPECIFIC ANTIGEN;

CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CANCER SURGERY; CELL SUBPOPULATION; DISEASE COURSE; EMERGENCY HEALTH SERVICE; GENETIC HETEROGENEITY; GENOME ANALYSIS; GENOMIC INSTABILITY; HUMAN; HYPOXIA; IMAGE GUIDED RADIOTHERAPY; LOCAL THERAPY; MALE; MEDICINE; PERSONALIZED MEDICINE; PRECISION MEDICINE; PREDICTOR VARIABLE; PROSTATE CANCER; RADIATION RESPONSE; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; BLOOD; CANCER STAGING; CHROMOSOMAL INSTABILITY; GENETIC SCREENING; GENETICS; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; RISK FACTOR;

CHROMOSOMAL INSTABILITY; GENETIC TESTING; HUMANS; MALE; NEOPLASM STAGING; OXYGEN CONSUMPTION; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RISK FACTORS;

EID: 84908268330     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20130753     Document Type: Review

References (96)

1. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 2005; 104: 891-905. doi: 10.1002/cncr.21257
2. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: 1320-4. doi: 10.1097/01.ju.0000049200.30192.d1
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72.
4. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 110: E431-2.
5. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013; 14: 97-108. doi: 10.1007/s11864-012-0221-5
6. Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013; 10: 473-82. doi: 10.1038/nrurol.2013.112
7. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012; 84: 104-11. doi: 10.1016/j.ijrobp.2011.10.069
8. Sridharan S, Dal Pra A, Catton C, Bristow RG, Warde P. Locally advanced prostate cancer: current controversies and optimisation opportunities. Clin Oncol (R Coll Radiol) 2013; 25: 499-505. doi: 10.1016/j.clon.2013.04.004
9. Mukherji D, Eichholz A, De Bono JS. Management of metastatic castrationresistant prostate cancer: recent advances. Drugs 2012; 72: 1011-28. doi: 10.2165/11633360-000000000-00000
10. Yap TA, Swanton C, de Bono JS. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J 2012; 3: 3. doi: 10.1007/s13167-011-0138-2
11. Kollmeier MA, Zelefsky MJ. How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol 2012; 84 (Suppl. 1): e6-15. doi: 10.1016/j.critrevonc.2012.12.002
12. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-77. doi: 10.1016/j.cell.2013.03.021
13. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res 2013; 73: 3275-84. doi: 10.1158/0008-5472.CAN-12-2803
14. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92. doi: 10.1038/nrc2344
15. Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 2007; 3: 329-41. doi: 10.2217/14796694.3.3.329
16. Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 2006; 64: 562-72. doi: 10.1016/j.ijrobp.2005.09.031
17. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clinical Cancer Res 2005; 11: 7658-63.
18. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 2006; 65: 91-9.
19. Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011; 38: 1816-23. doi: 10.1007/s00259-011-1876-z
20. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007; 67: 84-90.
21. Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostatecancer. Clinical Cancer Res 2012; 18: 2108-14.
22. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012; 107: 840-6. doi: 10.1038/bjc.2012.345
23. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys 2012; 82: e433-9.
24. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9: 342-51.
25. Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol 2012; 7: 66.
26. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408. doi: 10.1016/j.cell.2012.01.021
27. Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr 2013; 4: 5. doi: 10.1186/2041-9414-4-5
28. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol 2005; 15: 43-9. doi: 10.1016/j.semcancer.2004.09.007
29. Pollack A, Zagars GK, el-Naggar AK, Gauwitz MD, Terry NH. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 1994; 73: 1895-903.
30. Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, et al. Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol 2009; 31: 251-9. doi: 10.3233/CLO-2009-0463
31. Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, et al. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994; 74: 2811-18.
32. Song J, Cheng WS, Cupps RE, Earle JD, Farrow GM, Lieber MM. Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 1992; 147: 794-7.
33. Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clinical Cancer Res 2012; 18: 308-16.
34. Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, et al. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. Prostate 2012; 72: 1295-305. doi: 10.1002/pros.22478
35. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012; 118: 4053-62. doi:10.1002/cncr.26729
36. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-57.
37. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-4. doi: 10.1038/sj.bjc.6604453
38. Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 2013; 19: 5202-9.
39. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-88.
40. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, et al. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with highrisk prostate cancer. Clin Cancer Res 2010; 16: 195-202.
41. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011; 185: 1118-22. doi: 10.1016/j.juro.2010.10.035
42. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31: 978-91. doi: 10.1038/onc.2011.304
43. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
44. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22. doi: 10.1016/j.ccr.2010.05.026
45. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31: 1428-34. doi: 10.1200/JCO.2012.46.4396
46. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013; 8: e66855. doi: 10.1371/journal.pone.0066855
47. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011; 12: 245-55. doi: 10.1016/S1470-2045(10)70295-3
48. Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A 2013; 110: 6121-6. doi: 10.1073/pnas.1215870110
49. Cuzick J, Berney DM, Fisher G, Mesher D, Moller H, Reid JE, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012; 106: 1095-9. doi: 10.1038/bjc.2012.39
50. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86: 848-53.
51. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013; 190: 2047-53. doi: 10.1016/j.juro.2013.06.017
52. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusionnegative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012; 2: 1024-35. doi: 10.1158/2159-8290.CD-12-0041
53. Chao C, Chi M, Preciado M, Black MH. Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control 2013; 24: 1615-41. doi: 10.1007/s10552-013-0249-2
54. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, et al. Altered DNA methylation landscapes of polycombrepressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clinical Cancer Res 2013; 19: 3450-61.
55. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487-95. doi: 10.1158/2159-8290.CD-11-0130
56. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8. doi: 10.1038/nature05610
57. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007; 6: 923-35. doi: 10.1016/j.dnarep.2007.02.006
58. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68: 605-14. doi: 10.1158/0008-5472.CAN-07-5472
59. Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 2012; 125: 189-99. doi: 10.1242/jcs.092262
60. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, et al. Hypoxia downregulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76: 168-76. doi: 10.1016/j.radonc.2005.06.025
61. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 1998; 2: 259-65.
62. Kuhnert VM, Kachnic LA, Li L, Purschke M, Gheorghiu L, Lee R, et al. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 2009; 85: 523-31.
63. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003; 23: 3265-73.
64. Nakamura H, Tanimoto K, Hiyama K, Yunokawa M, Kawamoto T, Kato Y, et al. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxiainducible transcription factors, DEC1 and DEC2. Oncogene 2008; 27: 4200-9. doi: 10.1038/onc.2008.58
65. Rezvani HR, Mahfouf W, Ali N, Chemin C, Ged C, Kim AL, et al. Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res 2010; 38: 797-809. doi: 10.1093/nar/gkp1072
66. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 2007; 12: 3483-501.
67. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410. doi: 10.1038/nrc3064
68. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012; 11: 740-51. doi: 10.1158/1535-7163.MCT-11-0634
69. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009; 8: 203-13. doi: 10.1158/1535-7163.MCT-08-0959
70. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-64. doi: 10.1038/nrc2501
71. Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol 2011; 101: 59-65.
72. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70: 8045-54. doi: 10.1158/0008-5472.CAN-10-2352
73. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98. doi: 10.1038/nrc1691
74. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34. doi: 10.1056/NEJMoa0900212
75. Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010; 16: 4553-60. doi: 10.1158/1078-0432.CCR-10-0527
76. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010; 17: 235-48. doi: 10.1016/j.ccr.2009.12.046
77. MilosevicM, Chung P, Parker C, Bristow R, Toi A, Panzarella T, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007; 67: 6022-5.
78. Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T. Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res 2013; 19: 1547-56.
79. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A Hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013; 3: 1254-71. doi: 10.1158/2159-8290.CD-13-0108
80. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013; 3: 1245-53. doi: 10.1158/2159-8290.CD-13-0172
81. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010; 20: 274-81. doi: 10.1016/j.semradonc.2010.06.001
82. Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009; 100: 240-5. doi: 10.1038/sj.bjc.6604771
83. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5: 169ra10. doi: 10.1126/scitranslmed.3005211
84. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-65. doi: 10.1038/nm.1944
85. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgenindependent metastatic prostate cancer. Cancer Res 2008; 68: 3584-90. doi: 10.1158/0008-5472.CAN-07-6154
86. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92. doi: 10.1056/NEJMoa1113205
87. Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL. Circulating nucleic acids as biomarkers of prostate cancer. Biomark Med 2013; 7: 867-77. doi:10.2217/bmm.13.104
88. Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther 2014; 141: 209-21. doi: 10.1016/j.pharmthera.2013.10.004
89. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-12. doi: 10.1158/1078-0432.CCR-10-2650
90. Baumann M, Krause M, Thames H, Trott K, Zips D. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009; 85: 391-402. doi: 10.1080/09553000902836404
91. Woodward WA, Bristow RG. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semi Radiat Oncol 2009; 19: 87-95. doi: 10.1016/j.semradonc.2008.11.003
92. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, et al. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 2011; 6: e29170. doi:10.1371/journal.pone.0029170
93. Anderson KM, Guinan P, Rubenstein M. The effect of normoxia and hypoxia on a prostate (PC-3) CD44/CD41 cell side fraction. Anticancer Res 2011; 31: 487-94.
94. Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones G, et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J Cancer 2013; 109: 3023-33. doi: 10.1038/bjc.2013.691
95. Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev 2013; 9: 721-30. doi: 10.1007/s12015-013-9453-4
96. Chen X, Rycaj K, Liu X, Tang DG. New insights into prostate cancer stem cells. Cell Cycle 2013; 12: 579-86. doi: 10.4161/cc.23721